Transmucosal Drug Delivery Systems Market Scope And Analysis

Report Code : TIPRE00004209
Category : Life Sciences

No. of Pages : 150

Buy Now

Transmucosal Drug Delivery Systems Market Analysis, Size, and Growth (2021-2022)

Buy Now

Transmucosal Drug Delivery Systems Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 80.21 Billion
Market Size by 2031	US$ 129.46 Billion
Global CAGR (2023 - 2031)	6.2%
Historical Data	2021-2023
Forecast period	2023-2031
Segments Covered	By System Nasopulmonary Buccal & Sublingual Vaginal By End User Healthcare facilities Homecare Settings
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Teva Pharmaceutical Industries Ltd Cigna Corporation BioDelivery Sciences International Inc 3M Henkel Finland Oy GlaxoSmithKline plc Aquestive Therapeutics Inc Camurus AB Ximedica

Industry Developments and Future Opportunities:

The transmucosal drug delivery systems market forecast can help stakeholders in this marketplace plan their growth strategies. As per company press releases, a few strategic developments by leading players operating in the global market are listed below:

In February 2024, Aquestive Therapeutics, Inc. presented a poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting in Washington, DC, highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two complete clinical studies on sublingual Anaphylm (epinephrine) film.
In August 2022, iX Biopharma Ltd launched IXB-322, a new program to expand its pipeline. The program aims to develop a sublingual dexmedetomidine wafer for the treatment of agitation in dementia and other indications. This initiative is part of iX Biopharma's strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology.
In May 2021, Tillotts Pharma AG, a part of the Japanese Zeria Group, added a new medication to its gastroenterology portfolio with the launch of AsacolTM 1g (mesalazine). The high-strength suppository is used to treat mild to moderate ulcerative proctitis symptoms in adults. This launch will help the company offer innovative therapies to patients with gastrointestinal diseases. AsacolTM 1g suppositories provide a convenient form of treatment for individuals suffering from ulcerative proctitis, as they only require a single daily dose.
In April 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the release of its generic version of Casana 1 (mesalamine) suppository medicine. The medicine is indicated for the treatment of active ulcerative proctitis (ulcerative rectal colitis) in the US.

Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc are a few of the key companies profiled in the transmucosal drug delivery systems market report. These leading players focus on expanding and diversifying their market presence and clientele, tapping business opportunities in the market.